(Q53473361)

14 May 2018

title

Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. (English)

1 reference

14 May 2018

1 reference

Marcus C B Tan

1

1 reference

14 May 2018

David C Linehan

2

1 reference

14 May 2018

William G Hawkins

3

1 reference

14 May 2018

Barry A Siegel

4

1 reference

14 May 2018

Steven M Strasberg

5

1 reference

14 May 2018

publication date

11 July 2007

1 reference

14 May 2018

Journal of Gastrointestinal Surgery

published in

1 reference

14 May 2018

volume

11

1 reference

14 May 2018

page(s)

1112-1119

1 reference

14 May 2018

issue

9

1 reference

14 May 2018

https://scigraph.springernature.com/pub.10.1007/s11605-007-0218-8

exact match

0 references

cites work

PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11605-007-0218-8

Factors influencing the natural history of colorectal liver metastases

21 January 2018

1 reference

12 December 2020

Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development

1 reference

12 December 2020

Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma

1 reference

12 December 2020

Complete response of colorectal liver metastases after chemotherapy: does it mean cure?

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

Clinical role of FDG PET in evaluation of cancer patients

1 reference

12 December 2020

PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus

1 reference

12 December 2020

Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis

1 reference

12 December 2020

Long-term survival following resection of colorectal hepatic metastases. Association Française de Chirurgie.

1 reference

12 December 2020

Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases

1 reference

12 December 2020

The Brisbane 2000 terminology of liver anatomy and resections. HPB 2000; 2:333-39.

1 reference

12 December 2020

Use of PET for monitoring cancer therapy and for predicting outcome

1 reference

12 December 2020

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

1 reference

12 December 2020

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

12 December 2020

Positron emission tomography with F-18 fluorodeoxyglucose in evaluating colorectal hepatic metastasis down-staged by chemotherapy.

1 reference

12 December 2020

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic O

1 reference

12 December 2020

Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET).

1 reference

12 December 2020

Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer

1 reference

12 December 2020

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

12 December 2020

Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis

1 reference

12 December 2020

Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery

1 reference

12 December 2020

A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer

1 reference

12 December 2020

Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases

1 reference

12 December 2020

Detection and management of extrahepatic colorectal cancer in patients with resectable liver metastases

1 reference

12 December 2020

Resection of colorectal liver metastases

1 reference

12 December 2020

A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.

1 reference

12 December 2020

Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment

1 reference

12 December 2020

Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases

1 reference

12 December 2020

10.1007/S11605-007-0218-8

Identifiers

DOI

1 reference

14 May 2018

PubMed ID

17623263

1 reference

14 May 2018